Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study

Fig. 3

Expression of serum miR-22 is predictive of PFS in DLBCL patients. a Linear and logarithmic correlation between serum miR-22 values at diagnosis and days of PFS (Rho di Spearman = − 0.696; p < 0.001). b Kaplan–Meier curves for PFS in DLBCL patients with low (below median; solid line) and high (above median; dashed line) expression of miR-22. [p-value (log-rank test) = 0.007]

Back to article page